Form D · Biotechnology
Persephone Biosciences, Inc.
San Diego, CA · CIK 0001848850
Offering snapshot reported Mar 4, 2021 · SEC filing
- Reported sold
- $317K Offering amount: $317K
- Investors reported
- 24 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Feb 19, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 4, 2021 | Initial | $317,000 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-391291
Source: Form D, filed Mar 4, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephanie Culler | Director, Executive |
| Stephen Van Dien | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3210 Merryfield Row
San Diego, CA, 92121
San Diego, CA, 92121